Topotarget-medicine gets Orphan Drug-status
The European Medicines Agency (EMA) has approved a candidate drug from Topotarget as an Orphan Drug. The decision provides the Danish biotech company with far better conditions for developing the drug.
af LEONORA BECK
Topotarget’s candidate drug belinostat has achieved Orphan Drug-status in the EU for the treatment of the indication Peripheral T-Cell Lymphoma (PTCL).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish participation in American cancer meeting
For abonnenter
